| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Klinik für Anaesthesiologie der Technischen Universität München, Klinikum rechts der Isar, München, Germany.
Address correspondence to: Wolfram Reeker MD, Klinik für Anaesthesiologie der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 München, Germany. Phone: 49-89-4140-4291; Telefax: 49-89-4140-4829; Email: Wolfram.Reeker{at}lrz.tu-muenchen.de
Purpose: To determine the effects of the non-competitive NMDA-receptor antagonist S(+)-ketamine on neurological outcome in a rat model of incomplete cerebral ischemia.
Methods: Thirty rats were anesthetized, intubated and mechanically ventilated with isoflurane, O2 30% and nitrous oxide 70%. Following surgery animals were randomly assigned to one of the following treatment groups: Rats in group 1 (n=10, control) received fentanyl (bolus: 10 µgkg1 iv; infusion 25 µgkg1h1) and N2O 70% / O2. Rats in group 2 (n=10) received O2 30% in air and low-dose S(+)-ketamine (infusion: 0.25 mgkg1min1). Rats in group 3 (n=10) received O2 30% in air and high-dose S(+)-ketamine (infusion: 1.0 mgkg1min1). Following 30 min equilibration period ischemia was induced by combined unilateral common carotid artery ligation and hemorrhagic hypotension to 35 mmHg for 30 min. Plasma catecholamines were assayed before and at the end of ischemia. Neurological deficit was evaluated for three postischemic days.
Results: Neurological outcome was improved with high-dose S(+)-ketamine when compared to fentanyl / N2O - anesthetized controls (9 vs 1 stroke related deaths, P < 0.05). Increases in plasma catecholamine concentrations were higher in fentanyl / N2O anesthetized (adrenaline baseline 105.5 ± 92.1 pgml-1, during ischemia 948 ± 602.8 pgml-1, P < 0.05; noradrenaline baseline 407± 120.2 pgml-1, ischemia 1267 ± 422.2 pgml-1, P < 0.05) than in high-dose S(+)-ketamine-treated animals (adrenaline baseline 71 ± 79.5 pgml-1, ischemia 237 ± 131.9; noradrenaline baseline 317.9 ± 310.5 pgml-1, ischemia 310.5 ± 85.7 pgml-1).
Conclusion: Neurological outcome is improved following incomplete cerebral ischemia with S(+)-ketamine. Decreases in neuronal injury may be related to suppression of sympathetic discharge.
This article has been cited by other articles:
![]() |
S. Himmelseher and M. E. Durieux Revising a Dogma: Ketamine for Patients with Neurological Injury? Anesth. Analg., August 1, 2005; 101(2): 524 - 534. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Nagels, R. Demeyere, J. Van Hemelrijck, E. Vandenbussche, K. Gijbels, and E. Vandermeersch Evaluation of the Neuroprotective Effects of S(+)-Ketamine During Open-Heart Surgery Anesth. Analg., June 1, 2004; 98(6): 1595 - 1603. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Engelhard, C. Werner, E. Eberspacher, M. Bachl, M. Blobner, E. Hildt, P. Hutzler, and E. Kochs The Effect of the {alpha}2-Agonist Dexmedetomidine and the N-Methyl-D-Aspartate Antagonist S(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins After Incomplete Cerebral Ischemia and Reperfusion in Rats Anesth. Analg., February 1, 2003; 96(2): 524 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-M. Scheufler, C. Thees, J. Nadstawek, and J. Zentner S(+)-Ketamine Attenuates Myogenic Motor-Evoked Potentials at or Distal to the Spinal {alpha}-Motoneuron Anesth. Analg., January 1, 2003; 96(1): 238 - 244. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Engelhard, C. Werner, O. Mollenberg, and E. Kochs S(+)-ketamine/propofol maintain dynamic cerebrovascular autoregulation in humans : [Une combinaison de S(+)ketamine et de propofol maintient l'autoregulation vasculaire cerebrale dynamique chez l'humain] Can J Anesth, November 1, 2001; 48(10): 1034 - 1039. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |